Recombinant Hybrid GMZ-2 (African Malaria Network Trust)
N/A
Report date: 2022/12/31 17:30:28
Base Information
Drug NameRecombinant Hybrid GMZ-2 (African Malaria Network Trust)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesStatens Serum InstitutAfrican Malaria Network TrustSanaria Inc +[5]
China Registration ClassN/A
Develop Information
Active CompaniesEuropean Vaccine InitiativeEberhard-Karls Universitaet TuebingenStatens Serum Institut +[5]
Inactive CompaniesN/A
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A